GT Biopharma Inc (GTBP) Stock Price, Quote & News

Company Profile

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advan...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 919 4040

Website: www.gtbiopharma.com

Address:

315 Montgomery Street, 10th Floor, San Francisco, United States

Jessikah__Liu Oct. 25 at 7:55 PM

I like this. $EEIQ is def positioning for something and it could turn up to be the first 100% mover next week. Whatever their plans, it has great volatility and is a safe hold until well into next year. Thanks for bringing my attention to these others. I was watching the $SRZN action but completely missed $GTBP. And that one's a favorite of mine. Have you noticed the slow build $LBGJ has been making lately? That's a hard one to time but when it makes its move it's likely to be legendary.

0 · Reply

AStrokeOfLuck Oct. 24 at 9:19 PM

$GTBP https://www.sec.gov/Archives/edgar/data/109657/000149315225019296/forms-1.htm

1 · Reply

SmallCapAnalysis Oct. 24 at 4:51 PM

$GTBP Another afternoon pop

1 · Reply

prismmarketview Oct. 24 at 3:18 PM

(Nasdaq: $GTBP) #GTBiopharma advances its Phase 1 trial of GTB-3650 after completing Cohort 3 with no safety issues observed. Enrollment now open for Cohort 4 (10 µg/kg/day) — a key step toward defining efficacy in CD33+ blood cancers. Next update expected Q1 2026. https://prismmarketview.com/gt-biopharma-advances-phase-1-trial-of-gtb-3650-following-positive-safety-review/

0 · Reply

SkyLonger Oct. 24 at 9:45 AM

$GTBP doubler👀 ...soon enough 🤙

1 · Reply

nerowinger Oct. 23 at 7:30 PM

$GTBP added

0 · Reply

cninc Oct. 23 at 7:21 PM

$GTBP that was an odd jump in vol, interested to see how much more closing day vol above 1mil

0 · Reply

SmallCapAnalysis Oct. 23 at 6:40 PM

$GTBP Nice pop intraday 0.80 in ah ?

0 · Reply

SkyLonger Oct. 23 at 1:55 PM

$GTBP $2-3++ soon enough needs 👀s

0 · Reply

DARKP00L Oct. 23 at 1:34 PM

$GTBP 09:05 on Oct. 23 2025 GT Biopharma Completes Cohort 3 In GTB-3650 Formal Safety Review With No Safety Or Tolerability Issues Observed #tradeideas

0 · Reply

GT Biopharma Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 7:00 AM EDT - 2 months ago

GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2

Jun 13, 2025, 9:00 AM EDT - 4 months ago

GT Biopharma Appoints New Member to its Board of Directors

May 19, 2025, 9:00 AM EDT - 5 months ago

GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

Feb 25, 2025, 2:00 PM EST - 8 months ago

GT Biopharma Announces Exercise of Warrants

Nov 14, 2024, 4:00 PM EST - 1 year ago

GT Biopharma Reports Third Quarter 2024 Financial Results

Sep 26, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 24, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024

Jun 27, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

May 21, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

May 20, 2024, 10:43 AM EDT - 1 year ago

What made GT Biopharma stock more than double on Monday?

May 15, 2024, 5:00 PM EDT - 1 year ago

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mar 26, 2024, 5:00 PM EDT - 1 year ago

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Feb 1, 2024, 11:00 AM EST - 1 year ago

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

Dec 6, 2023, 9:30 AM EST - 2 years ago

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

Dec 4, 2023, 9:30 AM EST - 2 years ago

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

Nov 6, 2023, 9:30 AM EST - 2 years ago

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Nov 1, 2023, 9:00 AM EDT - 2 years ago

GT Biopharma Reports Third Quarter 2023 Financial Results

Aug 7, 2023, 9:00 AM EDT - 2 years ago

GT Biopharma Reports Second Quarter 2023 Financial Results

Aug 3, 2023, 1:25 PM EDT - 2 years ago

GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023

May 15, 2023, 5:00 PM EDT - 2 years ago

GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 4, 2023, 9:05 AM EDT - 2 years ago

GT Biopharma Names Charles J. Casamento to the Board of Directors

Mar 30, 2023, 5:00 PM EDT - 2 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

Feb 24, 2023, 9:00 AM EST - 2 years ago

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

Feb 2, 2023, 9:46 AM EST - 2 years ago

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

Dec 30, 2022, 8:00 AM EST - 3 years ago

GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market

Dec 14, 2022, 7:30 AM EST - 3 years ago

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

Dec 12, 2022, 7:30 AM EST - 3 years ago

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

Nov 10, 2022, 3:15 PM EST - 3 years ago

GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Nov 3, 2022, 9:00 AM EDT - 3 years ago

GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting

Oct 31, 2022, 5:15 PM EDT - 3 years ago

GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update

Oct 25, 2022, 2:44 PM EDT - 3 years ago

GT Biopharma Presents at LD Micro on October 26, 2022 at 4:30 pm PST

Oct 6, 2022, 8:18 AM EDT - 3 years ago

GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Oct 4, 2022, 4:10 PM EDT - 3 years ago

GT Biopharma Announces Adjournment of Special Shareholders Meeting

Sep 12, 2022, 9:34 AM EDT - 3 years ago

GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies

Sep 8, 2022, 7:30 AM EDT - 3 years ago

GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September

Aug 30, 2022, 6:00 PM EDT - 3 years ago

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

Aug 11, 2022, 9:35 AM EDT - 3 years ago

GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update

Jun 10, 2022, 8:00 AM EDT - 3 years ago

GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

May 16, 2022, 8:01 AM EDT - 3 years ago

GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update

May 12, 2022, 8:00 AM EDT - 3 years ago

GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference

Apr 11, 2022, 7:30 AM EDT - 3 years ago

GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022

Mar 28, 2022, 4:15 PM EDT - 3 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

Mar 21, 2022, 7:30 AM EDT - 3 years ago

GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting

Mar 9, 2022, 4:24 PM EST - 3 years ago

GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022

Mar 3, 2022, 7:30 AM EST - 3 years ago

GT Biopharma to Participate In-Person at 34th Annual ROTH Conference, March 13-15, 2022

Feb 24, 2022, 7:30 AM EST - 3 years ago

GT Biopharma to Present Pre-Clinical Data at Upcoming Medical Conferences

Feb 18, 2022, 7:30 AM EST - 4 years ago

GT Biopharma Appoints Manu Ohri as Chief Financial Officer

Jan 20, 2022, 7:30 AM EST - 4 years ago

GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference

Jan 6, 2022, 4:30 PM EST - 4 years ago

GT Biopharma Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Jessikah__Liu Oct. 25 at 7:55 PM

0 · Reply

AStrokeOfLuck Oct. 24 at 9:19 PM

$GTBP https://www.sec.gov/Archives/edgar/data/109657/000149315225019296/forms-1.htm

1 · Reply

SmallCapAnalysis Oct. 24 at 4:51 PM

$GTBP Another afternoon pop

1 · Reply

prismmarketview Oct. 24 at 3:18 PM

0 · Reply

SkyLonger Oct. 24 at 9:45 AM

$GTBP doubler👀 ...soon enough 🤙

1 · Reply

nerowinger Oct. 23 at 7:30 PM

$GTBP added

0 · Reply

cninc Oct. 23 at 7:21 PM

$GTBP that was an odd jump in vol, interested to see how much more closing day vol above 1mil

0 · Reply

SmallCapAnalysis Oct. 23 at 6:40 PM

$GTBP Nice pop intraday 0.80 in ah ?

0 · Reply

SkyLonger Oct. 23 at 1:55 PM

$GTBP $2-3++ soon enough needs 👀s

0 · Reply

DARKP00L Oct. 23 at 1:34 PM

$GTBP 09:05 on Oct. 23 2025 GT Biopharma Completes Cohort 3 In GTB-3650 Formal Safety Review With No Safety Or Tolerability Issues Observed #tradeideas

0 · Reply

AllHailTrump2024 Oct. 22 at 8:34 PM

$GTBP if you are a long or a newbie here, read this Article and learn what you hold. This bad boy is a part of the new A-team that will kick the shit out of cancer one day. You will see. Make money and save lives….the second one most important. https://www.prnewswire.com/news-releases/natural-killer-cell-therapies-lead-254b-immunotherapy-market-transformation-302587520.html

0 · Reply

AllHailTrump2024 Oct. 22 at 8:07 PM

$GTBP

0 · Reply

AllHailTrump2024 Oct. 22 at 6:39 PM

$GTBP what pattern is that??

0 · Reply

SmallCapAnalysis Oct. 22 at 1:38 PM

$GTBP Should hit 0.75/0.76 today based on pattern

0 · Reply

cninc Oct. 20 at 8:58 PM

$GTBP https://www.prnewswire.com/news-releases/natural-killer-cell-therapies-lead-254b-immunotherapy-market-transformation-302587520.html

0 · Reply

SkyLonger Oct. 20 at 7:14 PM

$GTBP giddy up over a buck

0 · Reply

wallstreet2025 Oct. 20 at 5:21 PM

$GTBP looked it up and some analysts saying 11 dollars. With a low float its possible IMO with some news to go parabolic Missed sprb so looking for a new moonshot which bio stocks are capable of

0 · Reply

SkyLonger Oct. 20 at 12:36 PM

$GTBP there you go✨️🚀

0 · Reply

PrimeTradingCorp Oct. 18 at 3:16 AM

$BCG 🚀 mooning wild! Up 40.4% to $3.16 from $2.25 open, golden cross on 5-min chart. 321K shares confirm squeeze—$10 EOY vibes! $YAAS Still on my watch list $MATH Back in my buy zone $AGAE and $GTBP watching to rebuy

0 · Reply

Gravy_Trains Oct. 17 at 4:37 PM

$BCG ✅Low/zero borrow. Bulls starting to squeeze it. We should see $4 run. Check out 52 week high $AREB Wow! That was fun $GPUS Added some more $LGHL and $GTBP back in buy zone

0 · Reply

SkyLonger Oct. 17 at 2:16 PM

$GTBP great news on GT biofarm expects to commence treatment for cohort 4 patients before end of 2025! Plenty of money fornops Q1 26 ✨️

0 · Reply

AllHailTrump2024 Oct. 16 at 4:34 PM

$GTBP Patience is the key here my people. This will rise

1 · Reply

Market Cap	2.60M
Revenue (ttm)	0.00
Net Income (ttm)	-13.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	743,400
Avg Vol	2,078,564
Day's Range	N/A - N/A
Shares Out	3.56M
Stochastic %K	27%
Beta	1.32
Analysts	Sell
Price Target	$11.00